Personalized Pathway-Activated Systems Imaging in Oncology : Principal and Instrumentation

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrum...

Full description

Saved in:
Bibliographic Details
Corporate Author: SpringerLink (Online service)
Other Authors: Inoue, Tomio. (Editor), Yang, David. (Editor), Huang, Gang. (Editor)
Format: eBook
Language: English
Published: Singapore : Springer Singapore : Imprint: Springer, 2017.
Subjects:
Medicine.
Nuclear medicine.
Oncology.
elektronické knihy
electronic books
ISBN: 9789811033490
Physical Description: XII, 243 p. 112 illus., 71 illus. in color. online resource.

Cover

Table of contents

LEADER 04610nam a22003975i 4500
001 101153
003 CZ-ZlUTB
005 20240914113239.0
006 m o d
007 cr nn 008mamaa
008 170302s2017 si | s |||| 0|eng d
020 |a 9789811033490 
024 7 |a 10.1007/978-981-10-3349-0  |2 doi 
245 1 0 |a Personalized Pathway-Activated Systems Imaging in Oncology :  |b Principal and Instrumentation /  |c edited by Tomio Inoue, David Yang, Gang Huang. 
264 1 |a Singapore :  |b Springer Singapore :  |b Imprint: Springer,  |c 2017. 
300 |a XII, 243 p. 112 illus., 71 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a počítač  |b c  |2 rdamedia 
338 |a online zdroj  |b cr  |2 rdacarrier 
505 0 |a Part 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) - Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin). 
506 |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty 
520 |a This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists-molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff. 
650 0 |a Medicine. 
650 0 |a Nuclear medicine. 
650 0 |a Oncology. 
655 7 |a elektronické knihy  |7 fd186907  |2 czenas 
655 9 |a electronic books  |2 eczenas 
700 1 |a Inoue, Tomio.  |e editor. 
700 1 |a Yang, David.  |e editor. 
700 1 |a Huang, Gang.  |e editor. 
710 2 |a SpringerLink (Online service) 
776 0 8 |i Printed edition:  |z 9789811033483 
856 4 0 |u https://proxy.k.utb.cz/login?url=http://dx.doi.org/10.1007/978-981-10-3349-0  |y Plný text 
992 |c NTK-SpringerMED 
999 |c 101153  |d 101153 
993 |x NEPOSILAT  |y EIZ 

Similar Items